Cargando…

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

SIMPLE SUMMARY: Chronic myeloid leukaemia (CML) is initiated by a group of cancer cells called leukaemia stem cells (LSC). These LSC can survive current tyrosine kinase inhibitor (TKI) treatments and, upon treatment withdrawal, are able to re-initiate the disease. Thus, eradicating the LSC would lik...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-Castañeda, Eduardo, Hopcroft, Lisa E. M., Rogers, Simon, Munje, Chinmay, Bittencourt-Silvestre, Joana, Copland, Mhairi, Vetrie, David, Holyoake, Tessa, Jørgensen, Heather G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655972/ https://www.ncbi.nlm.nih.gov/pubmed/36358672 http://dx.doi.org/10.3390/cancers14215253

Ejemplares similares

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
por: Kinstrie, Ross, et al.
Publicado: (2020)

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
por: Kinstrie, Ross, et al.
Publicado: (2020)

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
por: Patterson, Shaun David, et al.
Publicado: (2023)

Eradication of CML stem cells
por: Carter, Bing Z., et al.
Publicado: (2016)

Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
por: Bugler, Jane, et al.
Publicado: (2019)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
por: Lebecque, Benjamin, et al.
Publicado: (2022)

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
por: Trinh, Anne, et al.
Publicado: (2021)

Dual targeting of p53 and c-Myc selectively eliminates leukaemic stem cells
por: Abraham, Sheela A, et al.
Publicado: (2016)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

The LspC3–41I restriction-modification system is the major determinant for genetic manipulations of Lysinibacillus sphaericus C3–41
por: Fu, Pan, et al.
Publicado: (2017)

Validating a network hub in leukaemia stem cells
por: Hopcroft, Lisa E., et al.
Publicado: (2017)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors
por: Pellicano, Francesca, et al.
Publicado: (2014)

T315I(+) tyrosine-kinase independent CML cells resistance
por: Nicolini, Franck Emmanuel, et al.
Publicado: (2017)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
por: Foo, Jasmine, et al.
Publicado: (2009)

Comparison of the Transcriptomic Signatures in Pediatric and Adult CML
por: Youn, Minyoung, et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

MicroRNA signature refine response prediction in CML
por: Alves, Raquel, et al.
Publicado: (2019)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Novel oral transforming growth factor‐β signaling inhibitor EW‐7197 eradicates CML‐initiating cells
por: Naka, Kazuhito, et al.
Publicado: (2016)

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemic stem cells
por: Kuntz, Elodie M., et al.
Publicado: (2017)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α
por: Mehta, Adi, et al.
Publicado: (2011)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
por: Eadie, Laura N., et al.
Publicado: (2016)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022)

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia
por: Laidlaw, Kamilla M.E., et al.
Publicado: (2016)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

Significance Analysis of Microarrays (SAM) Offers Clues to Differences Between the Genomes of Adult Philadelphia Positive ALL and the Lymphoid Blast Transformation of CML
por: Grace, Colin, et al.
Publicado: (2012)

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
por: Carpiuc, Kimbach Tran, et al.
Publicado: (2010)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Hedgehog signaling in cancer stem cells: a focus on hematological cancers
por: Campbell, Victoria, et al.
Publicado: (2015)

Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nbp102u7s521fekauk33kurcf6